2nd International Conference on Alzheimers, Dementia and Related Neurodegenerative Diseases

International  # Conference  on  # Alzheimers , Dementia and Related  # Neurodegenerative  Diseases on December 03-04, 2018 in Madrid, Spain The  # theme  for the #conference is Leading  # Advancements  and  # Remedies in the #Neurodegenerative Disorders Know  # more  about the  # event  via:  https://bit.ly/2p9olWH # neurology   # research   # scientists   # students   # dementia   # neuroscience # delegates   # speakers

1 week more to go for the  #International   #Conference  on  #Alzheimers ,  #Dementia  and Related  #Neurodegenerative Diseases December 03-04, 2018 #Madrid  Spain The  #Scientific   #Program  for the  #conference  have been updated. Know more at  https://bit.ly/2PXb7bU #neurology   #scientists   #researchers   #speakers   #delegates   #finalcall   #neurodegeneration   #science

Epilepsy is a central nervous system (neurological) disorder in which brain activity becomes abnormal, causing seizures or periods of unusual behavior, sensations, and sometimes loss of awareness. Anyone can develop epilepsy. Epilepsy affects both males and females of all races, ethnic backgrounds and ages. Seizure symptoms can vary widely. Some people with epilepsy simply stares blankly for a few seconds during a seizure, while others repeatedly twitch their arms or legs. Having a single seizure doesn't mean you have epilepsy. At least two unprovoked seizures are generally required for an epilepsy diagnosis. Treatment with medications or sometimes surgery can control seizures for most people with epilepsy. Some people require lifelong treatment to control seizures, but for others, the seizures eventually go away. Some children with epilepsy may outgrow the condition with age. Symptoms Because epilepsy is caused by abnormal activity in the brain, seizur

Alzheimer’s disease is an irreversible, progressive brain disorder that slowly destroys memory and thinking skills, and eventually the ability to carry out the simplest tasks. In most people with Alzheimer’s, symptoms first appear in their mid-60s. Estimates vary, but experts suggest that more than 5.5 million Americans may have Alzheimer’s . Alzheimer's disease is currently ranked as the sixth leading cause of death in the United States, but recent estimates indicate that the disorder may rank third, just behind heart disease and cancer, as a cause of death for older people. Alzheimer’s is the most common cause of dementia among older adults. Dementia is the loss of cognitive functioning—thinking, remembering, and reasoning—and behavioral abilities to such an extent that it interferes with a person’s daily life and activities. Dementia  ranges in severity from the mildest stage, when it is just beginning to affect a person’s functioning, to the most severe stage, when

What Is Dementia ? Dementia is a general term for a decline in mental ability severe enough to interfere with daily life. Memory loss is an example. Alzheimer's is the most common type of dementia.   Dementia is not a specific disease. It's an overall term that describes a group of symptoms associated with a decline in memory or other thinking skills severe enough to reduce a person's ability to perform everyday activities. Alzheimer's disease accounts for 60 to 80 percent of cases. Vascular dementia , which occurs after a stroke, is the second most common dementia type. Symptoms of Dementia: While symptoms of dementia can vary greatly, at least two of the following core mental functions must be significantly impaired to be considered dementia : Memory Communication and language Ability to focus and pay attention Reasoning and judgment Visual perception Causes: Dementia is caused by damage to brain cells. This damage interferes with the abi

# Alzheimer’s Disease is a progressive disease that destroys memory and other important mental functions. # Brain cell connections and the cells themselves degenerate and die, eventually destroying memory and other important # mental functions. Memory loss and confusion are the main symptoms. No cure exists, but #medication and management strategies may temporarily improve symptoms. Although there’s no # cure , there are things you can do to help prevent, delay, or slow down Alzheimer’s disease and # dementia . Exercising regularly Getting a good night’s sleep Being MIND-ful about your diet Stress management Socializing Learning new things Lowering high blood pressure and cholesterol Losing weight Brushing and flossing Playing brain games Taking nutritional supplements Protecting your noggin Keeping your gut microbiome healthy Taking medications All of the above Know more at: https://alzheimers-dementia.pulsusconferenc

International #Conference on #Alzheimers, #Dementia and Related #Neurodegenerative Diseases is just 24 days away.. #Pulsus Group invites researchers from different fields of #Neurology to present their work at the event. The #conference will mainly focus on the following #topics: Track 1. Dementia Track 2. Alzheimer and Parkinson Track 3. Epilepsy Track 4. Multiple Sclerosis Track 5. Migraine Track 6. Prion Disease Track 7. Motor Neurone Diseases Track 8. Huntingtons Disease Track 9. Spinocerebellar Ataxia Track 10. Spinal Muscular Atrophy Track 11. Demyelinating Diseases Track 12. Cerebral Palsy Track 13. Cognitive Impairment Track 14. Stroke Track 15. Convulsion Track 16. Neurodegeneration Track 17. Neurorehabilitation Track 18. Neurology Track 19. Neuropathy Track 20. Headache Track 21. Neurologist Know more at:  https://alzheimers-dementia.pulsusconference.com/

What is the relationship between epilepsy and sleep apnoea? In previous studies it has been shown that a greater number of people with epilepsy also experience sleep apnoea , than in the general population. Researchers from Rutgers University wanted to develop a screening tool to detect sleep apnoea in patients with epilepsy as it is known that sleep apnoea can increase the number of seizures experienced. As lead author, Martha Mulvey, of the Department of Neurology , Rutgers New Jersey Medical School, said in a statement “Seizures can often be triggered by low oxygen levels that occur during obstructive sleep apnoea. Sleep deprivation and the interruption of sleep can therefore increase seizure frequency.” The idea being that if people with epilepsy can be screened for their risk of sleep apnoea , then this condition may be treated so that their epilepsy can be better controlled.   By developing this tool, the researchers showed that they were able to diagnose a

A gene therapy for Parkinson’s disease developed by Swiss biotech Axovant has been used on the first patient in a Phase I/II trial at University College London. Parkinson’s disease is a neurodegenerative disease , caused by a lack of the neurochemical dopamine in regions of the brain handling motor functions causing debilitating symptoms such as rigidity and tremors. Gene therapy has the potential to deliver therapeutics to specific areas of the brain, which would cause fewer side effects, such as hallucinations and compulsive behavior, than current treatments. Axovant’s gene therapy is designed to make the affected neurons produce dopamine by delivering the genetic instructions for making dopamine. The treatment is surgically injected into specific regions of the brain, and theoretically lasts for years after surgery . The first part of the trial will test the safety of different doses of the therapy. The second part will test its therapeutic effect on motor symp

Myelocortical multiple sclerosis (MS), a subtype of MS, is set apart by demyelination of the spinal cord and the cerebral cortex but not of cerebral white matter. Cortical neuronal loss may be enhanced in myelocortical MS cortex compared with typical MS cortex, according to study results published in The Lancet Neurology. Researchers examined the brains and spinal cords of deceased individuals with MS selected from the Cleveland Clinic rapid autopsy protocol. Brains were scanned using an MRI and then divided into hemispheres and matching slices. Of these, 12 brains did not have visible lesions in cerebral white matter or myelocortical MS . These brains and spinal cords were compared with those from 12 individuals with typical MS and 13 brains from individuals who did not have MS. Cerebral white-matter lesions per hemisphere were considerably greater in the typical MS group (10.0 (4.5 to 19.0) compared with the myelocortical MS group (0.5 (0.0 to 1.0). The typical size of in